![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Oxymed Australia Fined by TGA over COVID-19 Advertising Claims
Oxymed Australia Fined by TGA over COVID-19 Advertising Claims
![Fined $40,000](https://www.fdanews.com/ext/resources/test/Device_Images5/Fined-money-40000.gif?t=1587072484&width=430)
Australia’s Therapeutic Goods Administration (TGA) fined Oxymed Australia A$63,000 ($40,000) for making false claims that its hyperbaric oxygen therapy chambers can treat a variety of conditions, including COVID-19.
Oxymed’s claims are prohibited under therapeutic goods legislation and are “of significant concern to the TGA during the current pandemic,” the agency said.
The devices are not listed on the Australian Register of Therapeutic Goods, and unless an exemption applies, they cannot be legally supplied or advertised in Australia, the agency said.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct